abiraterone has been researched along with aromasil in 2 studies
Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (aromasil) | Trials (aromasil) | Recent Studies (post-2010) (aromasil) |
---|---|---|---|---|---|
942 | 97 | 854 | 897 | 245 | 492 |
Protein | Taxonomy | abiraterone (IC50) | aromasil (IC50) |
---|---|---|---|
Aromatase | Homo sapiens (human) | 0.1701 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Beijnen, JH; de Jong, KAM; de Vries, N; Rosing, H; van Nuland, M; Venekamp, N | 1 |
2 other study(ies) available for abiraterone and aromasil
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.
Topics: Administration, Oral; Anastrozole; Androstadienes; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Benzamides; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Nitriles; Phenylthiohydantoin; Tamoxifen; Tandem Mass Spectrometry; Tosyl Compounds | 2019 |